“One of my goals in life is to work on a novel drug that will extend and improve the quality of life for patients, so they can have more time to create beautiful memories with their families and friends. Working at Lycia has given me an opportunity to fulfill this dream, while being a part of a caring and nurturing team. Go Lycia! ”
Lycia Therapeutics
生物技术研究
South San Francisco，California 4,819 位关注者
Building the leading extracellular protein degradation company
Our Team
Our Mission
Developing first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases through our platform, potentially delivering next-generation therapeutics to address cancer, inflammation and autoimmune diseases.
Our Platform
We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins.
Carolyn Bertozzi's Glycorevolution Carolyn Bertozzi wins Nobel in chemistry